Author

Abderrahim Oukessou

Observed names: A Oukessou, A. Oukessou, Oukessou, A., Oukessou, Abderrahim

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Bristol-Myers Squibb (United States), Bristol-Myers Squibb (France)

OpenAlex ID: A5030713708

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

2021 · Luis Paz-Ares, Tudor-Eliade Ciuleanu, et al. · The Lancet Oncology · 1,357

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

2021 · Paul Baas, Arnaud Scherpereel, et al. · The Lancet · 1,206

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

2022 · Thomas John, Hiroshi Sakai, et al. · International Journal of Clinical Oncology · 34

Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study

2009 · Mauricette Michallet, Michel Tulliez, et al. · Current Medical Research and Opinion · 24

Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153

2018 · David Waterhouse, Leora Horn, et al. · Cancer Chemotherapy and Pharmacology · 19

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study

2018 · David Cella, Jan McKendrick, et al. · Annals of Hematology · 18

Kinetic of chronic myeloid leukaemia (CML) prevalence in Northern France since the introduction of imatinib

2008 · S. Corm, J. Micol, et al. · Journal of Clinical Oncology · 16

1311P First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA

2020 · T. John, H. Sakai, et al. · Annals of Oncology · 8

Alternative metrics for assessing clinical benefit with immunotherapy in oncology

2017 · E. Chan, C. Quinn, et al. · OncoImmunology · 7

Heterogeneity of treatment effects in malignant pleural mesothelioma – Authors' reply

2021 · Paul Baas, Arnaud Scherpereel, et al. · The Lancet · 4

Treatment Sequencing Patterns And Costs of Care in Patients with Relapsed/Refractory Multiple Myeloma

2015 · R Potluri, AM Farr, et al. · Value in Health · 3

A Retrospective 20-Year Survey of the Incidence of Chronic Myeloid Leukemia in the Northern France Region.

2006 · Selim Corm, Ariane Leroyer, et al. · Blood · 2

An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival

2015 · Gordon Cook, David Cella, et al. · Blood · 1

Caractéristiques et réponses aux traitements dans le mélanome stade III non opérable et stade IV : étude rétrospective longitudinale MELODY

2011 · C. Bedane, M.-T. Leccia, et al. · Revue d Épidémiologie et de Santé Publique

Pcn113 Treatment Patterns and Outcomes in the French Cohort of Patients With Unresectable Stage Iii or Stage Iv Melanoma (melody Study): a Retrospective Longitudinal Survey

2010 · C Bédane, MT Leccia, et al. · Value in Health

A Retrospective Survey of Imatinib Mesylate Treatment for Chronic Myeloid Leukemia in a Northern France Region.

2006 · Selim Corm, Ariane Leroyer, et al. · Blood

Works count: 18

Citation count: 2,695

H-index: 8

I10-index: 7